This section discusses what drives the cost, how price might influence access, and what support options patients could have
In a recent study, participants taking semaglutide were able to lose an average of 10.8 percent of their body weight over the course of 56 weeks, while those taking a placebo only lost 0.9 percent
MHRA-approved alternatives for weight management include semaglutide 2.4 mg (Wegovy), tirzepatide (Mounjaro), orlistat, and naltrexone/bupropion (Mysimba)
Combining Ozempic with a healthy diet and regular exercise may enhance its effectiveness in managing weight
While the epigenetic link is biologically plausible and supported by early evidence, more studies are needed to confirm if GLP-1 drugs truly act on addiction-related epigenetic changes, and how long these effects last
This helps avoid confusion and proves the medication is prescribed to you